The efficacy of vitamin D in multiple sclerosis: a review
DOI:
https://doi.org/10.12775/JEHS.2023.32.01.012Keywords
vitamin D, multiple sclerosis prevention, vitamin D deficiency, mulitple sclerosisAbstract
Introduction: Multiple sclerosis (MS) is a chronic, multifocal, inflammatory disease of the central nervous system (CNS) with an autoimmune basis. There is a strong correlation between vitamin D deficiency and the onset of multiple sclerosis and a more severe course of the disease and more severe comorbid symptoms. Many studies have investigated vitamin D supplementation to compensate for low 25(OH)D levels in MS patients.
Methods of research: A literature review was conducted based on PubMed, Google Scholar databese. Articles were researched using following keywords: multiple sclerosis; vitamin D; multiple sclerosis prevention; vitamin D deficiency.
The results: The results of these studies have provided important information on the safety and efficacy of vitamin D therapy in MS. Dietary vitamin D supplementation can therefore serve as a prevention of MS and as an adjunct to traditional MS therapy. However, it is important to emphasize the need to assess the risks and benefits individually for each patient.
References
Kamińska J, Koper OM, Piechal K, Kemona H. Multiple sclerosis - etiology and diagnostic potential. Postepy Hig Med Dosw (Online). 2017 Jun 30;71(0):551-563. doi: 10.5604/01.3001.0010.3836
Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathology (Zurich, Switzerland). 2007 Apr;17(2):210-218. DOI: 10.1111/j.1750-3639.2007.00064.x.
Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018 Apr 21;391(10130):1622-1636. doi: 10.1016/S0140-6736(18)30481-1. Epub 2018 Mar 23
Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. The New England Journal of Medicine. 2018 Jan;378(2):169-180. DOI: 10.1056/nejmra1401483
Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine. 2018 Sep;8(9):a028928. DOI: 10.1101/cshperspect.a028928.
Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clinical Medicine (London, England). 2016 Dec;16(Suppl 6):s53-s59. DOI: 10.7861/clinmedicine.16-6- s53
Brustad M, Meyer HE. Vitamin D--hvor mye er nok, og er mer bedre for helsen? [Vitamin D--how much is enough, and is more better for your Health?]. Tidsskr Nor Laegeforen. 2014 Apr 8;134(7):726-8. Norwegian. doi: 10.4045/tidsskr.13.1513.
Grossmann RE, Tangpricha V. Evaluation of vehicle substances on vitamin D bioavailability: a systematic review. Mol Nutr Food Res. 2010 Aug;54(8):1055-61. doi: 10.1002/mnfr.200900578.
Jagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, Robinson SA. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD008422. doi: 10.1002/14651858.CD008422.pub3
Heaney RP. Vitamin D in health and disease. Clinical Journal of the American Society of Nephrology: CJASN. 2008 Sep;3(5):1535-1541. DOI: 10.2215/cjn.01160308
Borel P, Caillaud D, Cano NJ. Vitamin D bioavailability: state of the art. Crit Rev Food Sci Nutr. 2015;55(9):1193-205. doi: 10.1080/10408398.2012.688897
Feige J, Moser T, Bieler L, Schwenker K, Hauer L, Sellner J. Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats. Nutrients. 2020 Mar 16;12(3):783. doi: 10.3390/nu12030783
Sun J, Zhang YG. Vitamin D Receptor Influences Intestinal Barriers in Health and Disease. Cells. 2022 Mar;11(7):1129. DOI: 10.3390/cells11071129
Bizzaro G, Antico A, Fortunato A, Bizzaro N. Vitamin D and Autoimmune Diseases: Is Vitamin D Receptor (VDR) Polymorphism the Culprit? Isr Med Assoc J. 2017 Jul;19(7):438-443
Simpson S Jr, Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1132-41. doi: 10.1136/jnnp.2011.240432. Epub 2011 Apr 8
Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol. 2010 Jun;9(6):599-612.
International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.
Rhead B., et al., Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet, 2016. 2(5): p. e97
Ascherio A., et al., Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol, 2014. 71(3): p. 306–14
Fitzgerald K.C., et al., Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol, 2015. 72(12): p. 1458–65
Runia T.F., et al., Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology, 2012. 79(3): p. 261–6
Muris AH, Smolders J, Rolf L, Thewissen M, Hupperts R, Damoiseaux J; SOLARIUM study group. Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study. J Neuroimmunol. 2016 Nov 15;300:47-56. doi: 10.1016/j.jneuroim.2016.09.018. Epub 2016 Oct 3
Jassil NK, Sharma A, Bikle D, et al. Vitamin D binding protein and 25- hydroxyvitamin D levels: emerging clinical applications. Endocr Practi. 2017;23:605– 613
Hashemi R, Morshedi M, Jafarabadi MA, et al. Anti-inflammatory effects of dietary vitamin D3 in patients with multiple sclerosis. Neurol Genet. 2018;4:e278
Behrens JR, Rasche L, Gieß RM, et al. Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. Eur J Neurol. 2016;23:62–67
Sotirchos ES, Bhargava P, Eckstein C, Van Haren K, Baynes M, Ntranos A, Gocke A, Steinman L, Mowry EM, Calabresi PA. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology. 2016 Jan 26;86(4):382-90. doi: 10.1212/WNL.0000000000002316. Epub 2015 Dec 30
Hartung HP, Graf J, Kremer D. Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. J Neurol. 2020 Feb;267(2):308-316. doi: 10.1007/s00415-018-09169-w. Epub 2019 Jan 4.
Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: Preliminary findings of a randomized-controlled trial. Iran J Neurol. 2015 Apr 4;14(2):67-73.
Munger KL, Åivo J, Hongell K, Soilu-Hänninen M, Surcel HM, Ascherio A. Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort. JAMA Neurol. 2016 May 1;73(5):515-9. doi: 10.1001/jamaneurol.2015.4800.
Camu W, Lehert P, Pierrot-Deseilligny C, Hautecoeur P, Besserve A, et al. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurol Neuroimmunol Neuroinflamm. 2019 Aug 6;6(5):e597. doi: 10.1212/NXI.0000000000000597. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2019 Nov 15;7(1)
Hupperts R, Smolders J, Vieth R, Holmøy T, Marhardt K, Schluep M, Killestein J, Barkhof F, Beelke M, Grimaldi LME; SOLAR Study Group. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology. 2019 Nov 12;93(20):e1906-e1916. doi: 10.1212/WNL.0000000000008445. Epub 2019 Oct 8.
Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, et al.; SOLAR study group. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci. 2011 Dec 15;311(1- 2):44-9. doi: 10.1016/j.jns.2011.04.013. Epub 2011 May 28.
Bäcker-Koduah P, Bellmann-Strobl J, Scheel M, Wuerfel J, Wernecke KD, Dörr J, Brandt AU, Paul F. Vitamin D and Disease Severity in Multiple Sclerosis-Baseline Data From the Randomized Controlled Trial (EVIDIMS). Front Neurol. 2020 Feb 25;11:129. doi: 10.3389/fneur.2020.00129.
Dörr J, Bäcker-Koduah P, Wernecke KD, Becker E, Hoffmann F, Faiss J, Brockmeier B, Hoffmann O, Anvari K, Wuerfel J, Piper SK, Bellmann-Strobl J, Brandt AU, Paul F. High-dose vitamin D supplementation in multiple sclerosis - results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. Mult Scler J Exp Transl Clin. 2020 Jan 24;6(1):2055217320903474. doi: 10.1177/2055217320903474.
Moosazadeh M, Nabinezhad-Male F, Afshari M, Nasehi MM, Shabani M, Kheradmand M, Aghaei I. Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis. AIMS Neurosci. 2021 Feb 5;8(2):239-253. doi: 10.3934/Neuroscience.2021013.
Bettencourt A, Boleixa D, Reguengo H, et al. Serum 25-hydroxyvitamin D levels in multiple sclerosis patients from the north of Portugal. J Steroid Biochem Mol Biol. 2018;180:137–141
Brola W, Sobolewski P, Szczuchniak W, et al. Association of seasonal serum 25- hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis. EurJ Clin Nutr. 2016;70:995–999
Kragt J, Van Amerongen B, Killestein J, et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler. 2009;15:9–15
Dupuis ML, Pagano MT, Pierdominici M, Ortona E. The role of vitamin D in autoimmune diseases: could sex make the difference? Biol Sex Differ. 2021 Jan 12;12(1):12. doi: 10.1186/s13293-021-00358-3.
Luchetti S, van Eden CG, Schuurman K, et al. Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions. J Neuropathol Exp Neurol. 2014;73:123–135
Ashtari, F.; Toghianifar, N.; Esfahani, S.H.Z.; Mansourian, M. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. Neurol. Res. 2016, 38, 888–892
Rolf, L.; Muris, A.-H.; Bol, Y.; Damoiseaux, J.; Smolders, J.; Hupperts, R. Vitamin D 3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression. J. Neurol. Sci. 2017, 378, 30–35
Kotb, M.A.; Kamal, A.M.; Aldossary, N.M.; Bedewi, M.A. Effect of vitamin D replacement on depression in multiple sclerosis patients. Mult. Scler. Relat. Disord. 2019, 29, 111–117
Beckmann, Y.; Türe, S.; Duman, S.U. Vitamin D deficiency and its association with fatigue and quality of life in multiple sclerosis patients. EPMA J. 2020, 11, 65–72
Taylor, K.L.; Simpson, S.J.; Jelinek, G.A.; Neate, S.L.; De Livera, A.M.; Brown, C.R.; O’Kearney, E.; Marck, C.H.; Weiland, T.J. Longitudinal Associations of Modifiable Lifestyle Factors With Positive Depression-Screen Over 2.5-Years in an International Cohort of People Living With Multiple Sclerosis. Front. Psychiatry 2018, 9, 526
Simpson-Yap, S.; Jelinek, P.; Weiland, T.; Nag, N.; Neate, S.; Jelinek, G. Selfreported use of vitamin D supplements is associated with higher physical quality of life scores in multiple sclerosis. Mult. Scler. Relat. Disord. 2021, 49, 102760
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Anna Rodzajewska, Weronika Kuryło
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 374
Number of citations: 0
